<DOC>
	<DOCNO>NCT01169779</DOCNO>
	<brief_summary>The purpose study evaluate benefit risk lixisenatide ( AVE0010 ) comparison placebo , add-on treatment metformin without sulfonylurea , period 24 week treatment . The primary objective ass effect glycemic control lixisenatide ( AVE0010 ) comparison placebo add-on treatment metformin without sulfonylurea term glycosylated hemoglobin ( HbA1c ) reduction ( absolute change ) Week 24 . The secondary objective assess effect lixisenatide 24 week percentage patient reach HbA1c le ( &lt; ) 7 percent ( % ) HbA1c le equal ( &lt; = ) 6.5 % , fast plasma glucose ( FPG ) , 2-hour postprandial plasma glucose ( PPG ) glucose excursion standardize meal test , body weight ; evaluate safety , tolerability , pharmacokinetic ( PK ) anti-lixisenatide antibody development .</brief_summary>
	<brief_title>Efficacy Safety Lixisenatide Patients With Type 2 Diabetes Mellitus Insufficiently Controlled Metformin</brief_title>
	<detailed_description>The study duration patient 27 week +/- 10 day ( 2 week screen + 1 week run-in + 24 week double-blind treatment + 3 day follow-up ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus , diagnose least 1 year screen visit , insufficiently control metformin alone metformin sulfonylurea time screen visit Exclusion criterion : HbA1c &lt; 7 % great ( &gt; ) 10 % screen At time screen age &lt; legal age majority Pregnant breastfeed woman woman childbearing potential effective contraceptive method Type 1 diabetes mellitus Treatment metformin stable dose least 1.0 gram per day 1.5 gram per day least 3 month prior screen visit In case treatment sulfonylurea , sulfonylurea dosage less maximum effective dose ( , half maximum recommend dose accord local labeling ) , stable ( unchanged ) dose least 3 month prior screen FPG screen &gt; 250 milligram per deciliter ( mg/dL ) ( &gt; 13.9 millimole per liter [ mmol/L ] ) History hypoglycemia unawareness Body mass index &lt; =20 kilogram per square meter ( kg/m^2 ) Weight change &gt; 5 kg 3 month precede screen visit History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease patient consider investigator high risk acute pancreatitis ( example , know history biliary gallstone [ ] , high triglyceride level [ &gt; =5.65 mmol/L ] ) time screen Personal family history medullary thyroid cancer genetic condition predispose medullary thyroid cancer ( example , multiple endocrine neoplasia syndrome ) ; History metabolic acidosis , include diabetic ketoacidosis within 1 year prior screen Hemoglobinopathy hemolytic anemia , receipt blood plasma product within 3 month prior time screen Within last 6 month prior screen : history myocardial infarction , stroke , heart failure require hospitalization Known history drug alcohol abuse within 6 month prior time screen Cardiovascular , hepatic , neurological , endocrine disease , active malignant tumor major systemic disease patient short life expectancy make implementation protocol interpretation study result difficult , history presence clinically significant diabetic retinopathy , history presence macular edema likely require laser treatment within study period Uncontrolled inadequately control hypertension time screen rest systolic blood pressure ( SBP ) diastolic blood pressure ( DBP ) &gt; 180 millimeter mercury ( mmHg ) &gt; 95 mmHg , respectively Laboratory finding time screening : amylase and/or lipase : &gt; 3 time upper limit normal ( ULN ) ; hemoglobin &lt; 11 gram/deciliter and/or neutrophil &lt; 1500 per cubic millimeter ( mm^3 ) and/or platelet &lt; 100 000/mm^3 ; calcitonin &gt; 20 picogram per milliliter ( 5.9 picomole per liter ) ; positive test Hepatitis B surface antigen and/or Hepatitis C antibody Any clinically significant abnormality identify physical examination , laboratory test , electrocardiogram , vital sign time screen , judgment investigator subinvestigator , preclude safe completion study constrain efficacy assessment Patients consider investigator subinvestigator inappropriate study reason ( example , impossibility meet specific protocol requirement , attend schedule visit , able selfinjections ; likelihood require treatment screen phase treatment phase drug permit clinical study protocol ; investigator subinvestigator , pharmacist , study coordinator , study staff relative thereof directly involve conduct protocol ) Use oral injectable antidiabetic hypoglycemic agent metformin sulfonylurea ( example , alphaglucosidase inhibitor , thiazolidinedione , glucagonlike peptide 1 [ GLP1 ] , receptor agonist , dipeptidylpeptidase4 inhibitor , insulin ) within 3 month prior time screen Use systemic glucocorticoid ( exclude topical application inhale form ) 1 week within 3 month prior time screen Use investigational drug within 3 month prior screen ; Participation previous study lixisenatide Renal impairment define creatinine &gt; 1.4 mg/dL woman creatinine &gt; 1.5 mg/dL men Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include , limited gastroparesis , unstable ( , worsen ) control ( , prolong nausea vomit ) gastroesophageal reflux disease require medical treatment , within 6 month prior time screen Allergic reaction GLP1 agonist past ( example , exenatide , liraglutide ) metacresol Additional exclusion criterion end runin phase : informed consent withdrawal ; lack compliance singleblind placebo runin phase ( &gt; 2 injection miss ) ; patient adverse event precludes inclusion study , assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>